Global Chimeric Antigen Receptor Cell Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Chimeric Antigen Receptor Cell Therapy Market Overview

• 1.1 Product Overview and Scope of Chimeric Antigen Receptor Cell Therapy
• 1.2 Classification of Chimeric Antigen Receptor Cell Therapy by Types
  • 1.2.1 Global Chimeric Antigen Receptor Cell Therapy Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Types in 2018
  • 1.2.3 Monotherapy
  • 1.2.4 Combination Therapy
• 1.3 Global Chimeric Antigen Receptor Cell Therapy Market by Application
  • 1.3.1 Global Chimeric Antigen Receptor Cell Therapy Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Acute Leukemia
  • 1.3.3 Non-hodgkin's Lymphoma
  • 1.3.4 Multiple Myeloma
  • 1.3.5 Transplant Rejection
  • 1.3.6 Other
• 1.4 Global Chimeric Antigen Receptor Cell Therapy Market by Regions
  • 1.4.1 Global Chimeric Antigen Receptor Cell Therapy Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
• 1.5 Global Market Size of Chimeric Antigen Receptor Cell Therapy (2014-2024)

2 Manufacturers Profiles

• 2.1 Amgen Inc
  • 2.1.1 Business Overview
  • 2.1.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Autolus Therapeutics Plc
  • 2.2.1 Business Overview
  • 2.2.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Beijing Immunochina Medical Science & Technology Co Ltd
  • 2.3.1 Business Overview
  • 2.3.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Bellicum Pharmaceuticals Inc
  • 2.4.1 Business Overview
  • 2.4.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Bristol-Myers Squibb Co
  • 2.5.1 Business Overview
  • 2.5.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 bluebird bio Inc
  • 2.6.1 Business Overview
  • 2.6.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 CARsgen Therapeutics Ltd
  • 2.7.1 Business Overview
  • 2.7.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Celgene Corp
  • 2.8.1 Business Overview
  • 2.8.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Cell Medica Ltd
  • 2.9.1 Business Overview
  • 2.9.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Cellular Biomedicine Group Inc
  • 2.10.1 Business Overview
  • 2.10.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Celularity Inc
  • 2.11.1 Business Overview
  • 2.11.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Celyad SA
  • 2.12.1 Business Overview
  • 2.12.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Daiichi Sankyo Co Ltd
  • 2.13.1 Business Overview
  • 2.13.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Fosun Pharmaceutical AG
  • 2.14.1 Business Overview
  • 2.14.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Gilead Sciences Inc
  • 2.15.1 Business Overview
  • 2.15.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Guangzhou Anjie Biomedical Technology Co Ltd
  • 2.16.1 Business Overview
  • 2.16.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Hangzhou Converd Co Ltd
  • 2.17.1 Business Overview
  • 2.17.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Hebei Senlang Biotechnology Inc Ltd
  • 2.18.1 Business Overview
  • 2.18.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 HRAIN Biotechnology Co Ltd
  • 2.19.1 Business Overview
  • 2.19.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Juno Therapeutics Inc
  • 2.20.1 Business Overview
  • 2.20.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Kite Pharma Inc
  • 2.21.1 Business Overview
  • 2.2.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Nanjing Legend Biotech Co Ltd
  • 2.22.1 Business Overview
  • 2.22.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 NantKwest Inc
  • 2.23.1 Business Overview
  • 2.23.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.24 Nkarta Inc
  • 2.24.1 Business Overview
  • 2.24.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.24.2.1 Product A
    • 2.24.2.2 Product B
  • 2.24.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.25 Novartis AG
  • 2.25.1 Business Overview
  • 2.25.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.25.2.1 Product A
    • 2.25.2.2 Product B
  • 2.25.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.26 Ono Pharmaceutical Co Ltd
  • 2.26.1 Business Overview
  • 2.26.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.26.2.1 Product A
    • 2.26.2.2 Product B
  • 2.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • 2.27.1 Business Overview
  • 2.27.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.27.2.1 Product A
    • 2.27.2.2 Product B
  • 2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.28 Sorrento Therapeutics Inc
  • 2.28.1 Business Overview
  • 2.28.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.28.2.1 Product A
    • 2.28.2.2 Product B
  • 2.28.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
• 2.29 Takara Bio Inc
  • 2.29.1 Business Overview
  • 2.29.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
    • 2.29.2.1 Product A
    • 2.29.2.2 Product B
  • 2.29.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)

3 Global Chimeric Antigen Receptor Cell Therapy Market Competition, by Players

• 3.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Chimeric Antigen Receptor Cell Therapy Players Market Share
  • 3.2.2 Top 10 Chimeric Antigen Receptor Cell Therapy Players Market Share
• 3.3 Market Competition Trend

4 Global Chimeric Antigen Receptor Cell Therapy Market Size by Regions

• 4.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Market Share by Regions
• 4.2 North America Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 4.3 Europe Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 4.5 South America Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

5 North America Chimeric Antigen Receptor Cell Therapy Revenue by Countries

• 5.1 North America Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
• 5.2 USA Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 5.3 Canada Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

6 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Countries

• 6.1 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
• 6.2 Germany Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 6.3 UK Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 6.4 France Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 6.5 Russia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 6.6 Italy Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Countries

• 7.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
• 7.2 China Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 7.3 Japan Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 7.4 Korea Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 7.5 India Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

8 South America Chimeric Antigen Receptor Cell Therapy Revenue by Countries

• 8.1 South America Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
• 8.2 Brazil Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Chimeric Antigen Receptor Cell Therapy by Countries

• 9.1 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 9.3 UAE Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

10 Global Chimeric Antigen Receptor Cell Therapy Market Segment by Type

• 10.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Market Share by Type (2014-2019)
• 10.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Type (2019-2024)
• 10.3 Monotherapy Revenue Growth Rate (2014-2024)
• 10.4 Combination Therapy Revenue Growth Rate (2014-2024)

11 Global Chimeric Antigen Receptor Cell Therapy Market Segment by Application

• 11.1 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Application (2014-2019)
• 11.2 Chimeric Antigen Receptor Cell Therapy Market Forecast by Application (2019-2024)
• 11.3 Acute Leukemia Revenue Growth (2014-2019)
• 11.4 Non-hodgkin's Lymphoma Revenue Growth (2014-2019)
• 11.5 Multiple Myeloma Revenue Growth (2014-2019)
• 11.6 Transplant Rejection Revenue Growth (2014-2019)
• 11.7 Other Revenue Growth (2014-2019)

12 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast (2019-2024)

• 12.1 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast (2019-2024)
• 12.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Regions (2019-2024)
• 12.3 North America Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
• 12.4 Europe Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
• 12.6 South America Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology